Recent News

• 08.06.2026 - Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
• 07.23.2026 - Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
• 07.16.2026 - Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
• 06.23.2026 - Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
• 06.04.2026 - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 05.27.2026 - Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
• 05.07.2026 - Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
• 05.06.2026 - Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
• 05.04.2026 - Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
• 04.30.2026 - Insmed to Present at May 2026 Investor Conferences

Recent Filings

• 08.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2026 - EX-99.1 EX-99.1
• 08.06.2026 - 8-K Current report
• 08.06.2026 - 144 Report of proposed sale of securities
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.24.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.23.2026 - 144 Report of proposed sale of securities
• 07.22.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.16.2026 - 8-K Current report